Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.

[1]  M. Muto,et al.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Shelley Tworoger,et al.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. , 2008, Gynecologic oncology.

[3]  A. Leminen,et al.  Updating on primary fallopian tube carcinoma , 2007, Acta Obstetricia et Gynecologica Scandinavica.

[4]  B. Karlan,et al.  Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. , 2007, Gynecologic oncology.

[5]  Kathleen M. Fairfield,et al.  Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. , 2007, American journal of epidemiology.

[6]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[7]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[8]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[9]  D. Fishman,et al.  Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. , 2007, The Lancet. Oncology.

[10]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[11]  Sadir J Alrawi,et al.  Aberrant crypt foci. , 2006, Anticancer research.

[12]  M. Nucci,et al.  Diagnostic Gynecologic and Obstetric Pathology , 2005 .

[13]  B. Karlan,et al.  BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? , 2005, Obstetrics and gynecology.

[14]  C. Mettlin,et al.  Age-specific ovarian cancer incidence rate patterns in the United States. , 2005, Gynecologic oncology.

[15]  L. Latonen,et al.  Cellular UV damage responses--functions of tumor suppressor p53. , 2005, Biochimica et biophysica acta.

[16]  D. Bell,et al.  Current issues in the pathology of ovarian cancer. , 2005, The Journal of reproductive medicine.

[17]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[18]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.

[19]  A. Whittemore,et al.  Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations , 2004, British Journal of Cancer.

[20]  A. Whittemore,et al.  Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. , 2004, American journal of epidemiology.

[21]  W. Murdoch,et al.  Oxidative Damage to DNA of Ovarian Surface Epithelial Cells Affected by Ovulation: Carcinogenic Implication and Chemoprevention , 2004, Experimental biology and medicine.

[22]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[23]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[24]  B. Stewart,et al.  World Cancer Report , 2003 .

[25]  R. Bast,et al.  Prevention of ovarian cancer: intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[27]  B. Rosen,et al.  Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.

[28]  S Wacholder,et al.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[29]  C. Isaacs,et al.  Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study , 2001, The Lancet.

[30]  K. Offit,et al.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.

[31]  G. Chenevix-Trench,et al.  Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. , 1998, Journal of the National Cancer Institute.

[32]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[33]  G. Chenevix-Trench,et al.  Relationship Between Number of Ovulatory Cycles and Accumulation of Mutant p 53 in Epithelial Ovarian Cancer , 1998 .

[34]  A. Berchuck,et al.  Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. , 1997, Journal of the National Cancer Institute.

[35]  F. Pontén,et al.  Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. , 1997, The American journal of pathology.

[36]  A S Whittemore,et al.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. , 1997, American journal of human genetics.

[37]  M. Wells,et al.  p53 protein expression in putative precursor lesions of epithelial ovarian cancer , 1995, Histopathology.

[38]  R. Scully,et al.  Early de novo ovarian carcinoma. A study of fourteen cases , 1994, Cancer.

[39]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[40]  M. Friedlander,et al.  Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases , 1989, Cancer.

[41]  C. Becker,et al.  Cancer Prevention , 1955, Definitions.